JIR
SUPN icon

James Investment Research’s Supernus Pharmaceuticals SUPN Stock Holding History

James Investment Research’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Hold
21,004
– – 0.1% 185
2026
Q1 		$1.09M Buy
21,004
+29
+0.1% +$1.48K 0.12% 158
2025
Q4 		$1.04M Hold
20,975
– – 0.11% 156
2025
Q3 		$1M Buy
20,975
+3,332
+19% +$134K 0.11% 161
2025
Q2 		$556K Hold
17,643
– – 0.07% 205
2025
Q1 		$578K Hold
17,643
– – 0.07% 195
2024
Q4 		$638K Sell
17,643
-1
-0% -$35 0.08% 191
2024
Q3 		$550K Buy
17,644
+5,022
+40% +$157K 0.06% 207
2024
Q2 		$338K Buy
+12,622
New +$366K 0.04% 257

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

James Investment Research's SUPN Position: Q2 2026 in Review

James Investment Research held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 21,004 shares worth $977K. The position accounts for 0.1% of the portfolio, ranked #185.

James Investment Research first reported a position in SUPN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.09M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • James Investment Research held 21,004 shares of Supernus Pharmaceuticals worth $977K as of Q2 2026.
  • James Investment Research left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up 0.1% of James Investment Research's portfolio in Q2 2026, its #185 holding.
  • James Investment Research first reported a position in Supernus Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • James Investment Research's Supernus Pharmaceuticals position peaked at $1.09M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.